NCT05975554 (ELLIPSE) is a NA clinical trial of Interleukin-2 [IL-2] in TIA, sponsored by Cambridge University Hospitals NHS Foundation Trust.

Who is sponsoring NCT05975554?

NCT05975554 is sponsored by Cambridge University Hospitals NHS Foundation Trust.

What drugs are being tested in NCT05975554?

Interventions in NCT05975554: Interleukin-2 [IL-2], Standard care - Carotid Endarterectomy.

What condition does NCT05975554 study?

NCT05975554 studies TIA, Carotid Artery Plaque, Carotid Atherosclerosis.

Is NCT05975554 still recruiting?

NCT05975554 is currently active, enrolled. Last updated 30 May 2025.

Last reviewed 2025-05-30 · How we verify

NCT05975554: ELLIPSE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.

Active, enrolled NA Last updated 30 May 2025

What this trial tests

NA trial testing Interleukin-2 [IL-2] in TIA in 30 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

26 August 2023

Primary endpoint
1 February 2025

1 September 2025

Quick facts

Lead sponsor	Cambridge University Hospitals NHS Foundation Trust
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	30
Start date	26 August 2023
Primary completion	1 February 2025
Estimated completion	1 September 2025
Sites	1 location across United Kingdom

Drugs / interventions tested

Interleukin-2 [IL-2]
Standard care - Carotid Endarterectomy

Conditions studied

TIA — all drugs for TIA →
Carotid Artery Plaque — all drugs for Carotid Artery Plaque →
Carotid Atherosclerosis — all drugs for Carotid Atherosclerosis →

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Who can join

18 and older, any sex, with TIA or Carotid Artery Plaque. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trail is to compare the differences in carotid plaque Treg cells' gene signature for activation, proliferation, and suppressive function using scRNA-seq in patients treated with IL-2 compared to control.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic Avenues to Modulate B-Cell Function in Patients With Cardiovascular Disease.
O'Brien JW, Case A, Kemper C, Zhao TX, et al · · 2024 · cited 7× · PMID 38813699 · DOI 10.1161/atvbaha.124.319844
Fluorescence-Activated Cell Sorting Depletes Macrophages and Triggers Inflammation in the Single-Cell Immune Landscape of Human Atherosclerosis.
Case AG, O'Brien JW, Charlier FTW, Al-Hadithi ABAK, et al · · 2025 · PMID 40469035 · DOI 10.1161/atvbaha.125.322856

Verify or expand the search:

Other trials of Interleukin-2 [IL-2]

Trials testing the same drug.

NCT04241601 — Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY · Phase 2 · completed

Other recruiting trials for TIA

Currently open trials in the same condition.

NCT06986954 — Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study · recruiting
NCT06315192 — Stroke Alarm Efficacy Trial · NA · recruiting
NCT06225752 — Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis · Phase 3 · recruiting
NCT06495073 — Determining the MCID for the TOPICS-SF and PROMIS-10 in Older Patients That Suffered an Ischemic Stroke or TIA · recruiting
NCT06605014 — Somatic Dysfunction in Patients With Acute Cerebrovascular Disease · recruiting

Other Cambridge University Hospitals NHS Foundation Trust trials

Trials by the same sponsor.

NCT07516496 — Metabolic Phenotyping in vEDS · recruiting
NCT07129577 — Point of Care Testing in Emergency Departments After Mild Traumatic Brain Injury · not yet recruiting
NCT05093231 — Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer · Phase 2 · recruiting
NCT06555757 — Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation · not yet recruiting
NCT06427694 — Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05975554 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cambridge University Hospitals NHS Foundation Trust
Last refreshed: 30 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05975554.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing